Huperzine A
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
1
Recruiting
0
Completed
1
Sites
30
Countries
2
Endpoints
7
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 7 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 3 of 7 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
1
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT00083590Huperzine A in Alzheimer's Disease | Huperzine A Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 29 | Nov 2007 | 2 | |
| NCT01282619Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease | Huperzine A Alzheimer’s disease | Alzheimer's disease | Ph 2/3 | Unknown | 1 | Jun 2012 | - | |
| NCT02931136Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging | Huperzine A Alzheimer’s disease, MCI / preclinical Alzheimer’s | Age 55-85 | Ph 4 | Unknown | 1 | Dec 2024 | - | |
| NCT07066826Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type | Donepezil, Huperzine A Alzheimer’s disease | Alzheimer's disease | Ph 2/3 | Not yet recruiting | 0 | Aug 2028 | - |
Showing 1-4 of 4 trials